Molecular features of aggressive prostate carcinoma

Abstract

Prostate cancer is the most common form of malignancy in the male urinary tract and accounts for more than 20% of all newly diagnosed male cancer cases. The vast majority of prostate tumours are clinically insignificant, occurring in elderly patients who are unlikely to experience progression within their lifetime. However, rising incidence and mortality rates would testify that prostate cancer has the propensity to be an aggressive and fatal systemic malignancy. Despite the prevalence of this non-cutaneous malignancy, the pathobiology underlying the observed clinical heterogeneity of prostate cancer remains poorly delineated.